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Cigarette combustion, rather than either tobacco or nicotine, is the cause of a public health disaster. Fortunately,
several new technologies that vaporize nicotine or tobacco, and may make cigarettes obsolete, have recently
appeared. Research priorities include the effects of vaporizers on smoking cessation and initiation, their safety and
toxicity, use by non-smokers, dual use of vaporizers and cigarettes, passive vaping, renormalization of smoking,
and the development of messages that effectively communicate the continuum of risk for tobacco and nicotine
products. A major difficulty is that we are chasing a moving target. New products constantly appear, and research
results are often obsolete by the time they are published. Vaporizers do not need to be safe, only safer than
cigarettes. However, harm reduction principles are often misunderstood or rejected. In the context of a fierce
ideological debate, and major investments by the tobacco industry, it is crucial that independent researchers provide
regulators and the public with evidence-based guidance. The methodological and ideological hurdles on this path are
discussed in this commentary.
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The combustion of cigarettes, rather than either tobacco
or nicotine, is the cause of a public health disaster. The
cigarette-rolling machine, an innovation of the 19th cen-
tury, bears much of the responsibility for this disaster.
However, a series of 21st century innovations have the
potential to revert the statistics back to the very low
levels of tobacco-related mortality that existed before
the advent of manufactured cigarettes, when tobacco
was used mainly in non-combustible forms. Recent in-
novations include electronic cigarettes, vaporizers that
heat tobacco but do not burn it, products similar to
asthma inhalers that produce a nicotine aerosol, prod-
ucts that use a chemical reaction (pyruvate) to vaporize
nicotine and products that use a flow of hot air to
vaporize tobacco [1-4]. Given the profitability of this
market, there is little doubt that other types of vaporizers
will soon appear.
Scientists and regulators often react in a confused way
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unless otherwise stated.ideological, and arguments are often misleading and even
dishonest [5]. Negative reports on e-cigarettes tend to re-
ceive much media coverage, and, as a result, the propor-
tion of smokers who think that e-cigarettes are more
dangerous than combustible cigarettes is increasing [6]. In
this context, it is crucial to provide regulators, clinicians,
journalists and consumers with sound, evidence-based
responses to their questions. However, there are hurdles
on this path, both methodological and ideological.Research priorities
The impact of e-cigarettes and vaporizers on public
health is the product of the damage caused or prevented
by such products, multiplied by the number of people
who adopt these products and stop using combustible
cigarettes. From a regulatory point of view, the objective
should be to minimize the harm to the population caused
by all nicotine and tobacco products, including combust-
ible cigarettes. Researchers should provide evidence to
help regulators write reasonable regulations that take into
account a continuum of risk for nicotine and tobacco
products, are based on a principle of proportionality and
do not stifle innovation. Research priorities include thean Open Access article distributed under the terms of the Creative Commons
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safety and toxicity, use by non-smokers, dual use of vapor-
izers and cigarettes, use in public places (exposure to pas-
sive vaping and renormalization of smoking), flavors
(toxicity and behavioral effects), nicotine (addictiveness,
toxicity, risk perception) and the development of messages
that effectively communicate the continuum of risk.
Methodological issues
A major difficulty is that we are chasing a moving target.
New products appear all the time, and research findings
are often obsolete by the time they are published.
Most published studies on e-cigarettes are relatively
short-term, but it is crucial to assess the long-term ef-
fects of these products on health and behavior. This will
be costly and take years, and long-term studies will be
outdated by the time they are published.
One important question is to assess whether e-cigarettes
are a gateway to smoking or nicotine dependence in young
non-smokers. We know from research on illicit drugs
(is cannabis a gateway to heroin?) that proving gateway
effects requires methodologically sophisticated studies
[7]. For e-cigarettes, all published studies to date that
address gateway effects fall short of these methodological
requirements [4,8].
Assessing the effects of passive exposure to e-cigarette
vapors is also politically relevant. However, given the very
low levels of risk involved (probably orders of magnitude
lower than for cigarette smoke), any health effect will be
very hard to detect.
Ideological bias
There is a continuum of risk for nicotine-containing prod-
ucts [9,10]. Harm reduction is about the lesser of two
evils: vaporizers need to be safer than cigarettes, but not
necessarily safe. Failure to admit this leads to negative atti-
tudes towards reduced-risk products and to regulations
that apply the same restrictions to all products. This is
damaging to public health, as it hampers alternatives to
combustible cigarettes. In many countries, nicotine vapor-
izers and smokeless tobacco cannot currently be advertised
as reduced-risk products. Laws that prevent truthful com-
munication about this continuum of risk prevent adoption
of less harmful alternatives to combustible cigarettes.
The debate is loud but lacks robustness, and there is
often an ideological bias against, and a lack of understand-
ing of, harm reduction principles. There is also a willing-
ness of the press and some scientists to emphasize the
negative effects of e-cigarettes [5]. In particular, press
releases issued by scientists or by their institutions
sometimes do not reflect research findings [11]. This
could be prevented by submitting press releases to the
same peer-review process as that for scientific articles.
The public has the right to an objective assessment of thesituation, and to appropriate guidance, but at present this
is not what it gets from many scientific articles, press
reports and institutions [5,11,12].
Conflicts of interest
Most e-cigarette manufacturers have shown little inter-
est in conducting or supporting peer-reviewed research.
Much of the research is, therefore, conducted by inde-
pendent researchers, but conflicts of interest are never-
theless present [1]. In contrast, research on other types
of vaporizers (for example, heated tobacco products) is
mainly conducted by the tobacco industry. For instance,
Philip Morris International invested $2bn in research
and development efforts for their four new vaporizing
technologies [13]. To counterbalance this enormous
investment, other funding sources (governments, founda-
tions, crowdfunding) are needed to support independent
researchers. A small tax (a few cents per unit) could be
imposed on vaporizers to support independent research
and education, but otherwise these products should be
given a tax incentive.
The tobacco industry will probably soon dominate the
nicotine/tobacco vaporizers market, not least because ex-
cessive regulation will make it too costly for smaller players
to survive in a highly regulated environment. The tobacco
industry will then be in a position to stifle this market, if it
ends up being less profitable than tobacco cigarettes.
Because of the dominant position of the tobacco industry,
researchers and their institutions have little choice but to
(reluctantly) reconsider their attitudes towards this indus-
try. This is one of the thorniest issues in this field. The
disclosure of conflicts of interest and registration of studies
in open registries are necessary but insufficient first steps.
An open debate, involving all stakeholders, is needed on
this issue. Transparency and an appropriate approach to
the management of conflicts of interest are necessary to
preserve the integrity of research and public trust.
Conclusions
A window of opportunity is now open but will soon close.
In the United States, the Food and Drug Administration is
developing regulations that will apply to e-cigarettes and
vaporizers, and European Union Member States are now
transposing the Tobacco Products Directive into national
laws. Once these regulations are in place, they will be very
difficult to change. However, because harm reduction
strategies are often misunderstood or rejected [14], there
is a risk that e-cigarettes and vaporizers will be excessively
regulated. Regulators must consider the unintended conse-
quences of excessive regulation, and should be held account-
able for any such consequences. Given that e-cigarettes
and vaporizers are already much safer than combustible
cigarettes, any benefit of regulations will be small,
whereas the unintended consequences can have a large
Etter BMC Medicine  (2015) 13:32 Page 3 of 3negative impact. Unfortunately, current proposals for
regulation are often worse than the status quo. It is sad
that this is happening with the help of some public health
professionals, scientists and elected representatives of the
people.
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